CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia

NCT00142168 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

16

Enrollment

OTHER

Sponsor class

Stopped Toxicity

Conditions

Waldenstrom's Macroglobulinemia

Interventions

DRUG: CC-5103 (lenalidomide)
DRUG: Rituximab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]